- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Methylphenidate HCl ER tablets 1, Placebo, Methylphenidate HCl ER tablets 2, Methylphenidate HCl ER for suspension
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Las Vegas, Nevada
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 776
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC), Nonsmall Cell Lung Cancer, Stage IIIB, Nonsmall Cell Lung Cancer, Stage IV
- Interventions
- Ociperlimab, Tislelizumab, Carboplatin, Paclitaxel, Nab paclitaxel, Cisplatin, Pemetrexed, Placebo
- Drug
- Lead sponsor
- BeiGene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 272 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Iowa City, Iowa • Las Vegas, Nevada + 8 more
- Conditions
- Attention Deficit Disorder With Hyperactivity
- Interventions
- high dose clonidine HCl sustained release, low dose clonidine HCl sustained release, placebo
- Drug
- Lead sponsor
- Addrenex Pharmaceuticals, Inc.
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 236 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 13
- States / cities
- Gainesville, Florida • Jacksonville, Florida • Miami, Florida + 9 more
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- vortioxetine 10 mg tablet, vortioxetine 20 mg tablet, Placebo tablet
- Drug · Other
- Lead sponsor
- H. Lundbeck A/S
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 227 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 15
- States / cities
- Beverly Hills, California • Garden Grove, California • National City, California + 11 more
- Conditions
- Prescription Drug Abuse (Not Dependent), Intentional Misuse
- Interventions
- Web-based placebo presentation, Web-based simulation active intervention
- Other · Behavioral
- Lead sponsor
- Trinity College
- Other
- Eligibility
- 17 Years to 25 Years
- Enrollment
- 249 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 3
- States / cities
- Hartford, Connecticut • San Marcos, Texas • Laramie, Wyoming
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Interventions
- vorinostat, paclitaxel, carboplatin, placebo, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Atomoxetine
- Drug
- Lead sponsor
- Monarch Medical Research
- Other
- Eligibility
- 6 Years to 18 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Norfolk, Virginia
- Conditions
- Healthy Males
- Interventions
- Acyline, Testosterone gel, ketoconazole 400, Ketoconazole 800, Dutasteride, Anastrozole, Placebo ketoconazole
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 50 Years · Male only
- Enrollment
- 46 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Epstein-Barr Virus Infection, Infectious Mononucleosis, Herpesvirus
- Interventions
- Matrix-M1 Adjuvant, EBV gp350-Ferritin Vaccine, Placebo Comparator
- Drug · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 25 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • Minneapolis, Minnesota
- Conditions
- Cystic Fibrosis
- Interventions
- Inhaled Vancomycin, Placebo (Sterile Water), Rifampin, Trimethoprim/Sulfamethoxazole (TMP/SMX), Doxycycline, Mupirocin Intranasal Creme, 4% chlorhexidine gluconate liquid skin cleanser
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Cleveland, Ohio
- Conditions
- Atrial Fibrillation, Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation
- Interventions
- OPC-108459, Placebo
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 9
- States / cities
- Washington D.C., District of Columbia • Hollywood, Florida • Jacksonville, Florida + 6 more
- Conditions
- Attention, Memory, Alertness
- Interventions
- oréVida™, Placebo
- Dietary Supplement
- Lead sponsor
- dsm-firmenich Switzerland AG
- Industry
- Eligibility
- 35 Years to 50 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Addison, Illinois
- Conditions
- Tobacco Dependence
- Interventions
- Nicotine Containing ECIG with tobacco flavor, Nicotine Containing ECIG with Strawberry Vanilla Flavor, Placebo ECIG with Tobacco Flavor, Placebo ECIG with Strawberry Vanilla Flavor
- Other
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 21 Years to 60 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- Tympanic Membrane Perforation
- Interventions
- FGF-2, Placebo
- Drug · Other
- Lead sponsor
- D. Bradley Welling, MD, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Lackland City, Texas
- Conditions
- Healthy Volunteer
- Interventions
- TRL1068, a human monoclonal antibody
- Drug
- Lead sponsor
- Trellis Bioscience LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Alcohol Drinking, Alcohol Use Disorder
- Interventions
- Ketone Ester "(R)-3-hydroxybutyl (R)-3-hydroxybutyrate", Isocaloric dextrose placebo, Alcohol drinks
- Dietary Supplement · Drug · Other
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Intermittent Explosive Disorder
- Interventions
- Cognitive Bias Modification, Cognitive Bias Control
- Behavioral
- Lead sponsor
- Temple University
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Subcutaneous Fat
- Interventions
- CBL-514 Injection, 0.9% Sodium Chloride
- Drug · Other
- Lead sponsor
- Caliway Biopharmaceuticals Co., Ltd.
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 107 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Pflugerville, Texas
- Conditions
- Modified Release Oral Formulation, Left Ventricular Systolic Dysfunction, Chronic Heart Failure, History of Chronic Heart Failure, Left Ventricular Ejection Fraction, Pharmacokinetics, Echocardiogram
- Interventions
- Omecamtiv Mecarbil Matrix F1 Formulation, Omecamtiv Mecarbil Matrix F2 Formulation, Placebo, Omecamtiv Mecarbil Swellable Core Technology F2
- Drug
- Lead sponsor
- Cytokinetics
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 544 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 38
- States / cities
- Mobile, Alabama • Costa Mesa, California • Fresno, California + 34 more
- Conditions
- Peanut Allergy
- Interventions
- CNP-201, Placebo
- Drug
- Lead sponsor
- COUR Pharmaceutical Development Company, Inc.
- Industry
- Eligibility
- 16 Years to 55 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Long Beach, California • Mission Viejo, California + 13 more
- Conditions
- Crohn's Disease, Inflammatory Bowel Disease
- Interventions
- Active fructo-oligosaccharide, Placebo fructo-oligosaccharide, Diet
- Drug · Dietary Supplement
- Lead sponsor
- Rush University Medical Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 2
- States / cities
- Macon, Georgia • Chicago, Illinois
- Conditions
- Alcohol Use Disorder (AUD), Post Traumatic Stress Disorder (PTSD)
- Interventions
- Placebo, Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg, Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µg, Ethanol Infusion, PTSD Reactivity Condition, Alcohol Cue Reactivity
- Drug · Procedure · Behavioral
- Lead sponsor
- Pharmacotherapies for Alcohol and Substance Use Disorders Alliance
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- West Haven, Connecticut
- Conditions
- Anxiety Disorders
- Interventions
- Progressive Muscle Relaxation, Diaphragmatic Breathing, Psychoeducation (Placebo)
- Behavioral · Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 60 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Healthy
- Interventions
- BAF 312
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey